Oct. 31 at 10:24 AM
$ATR
Aptar (
$ATR) Reports Solid Q3 2025 Results, Confident in Injectables Growth
Aptar reports robust Q3 2025 performance. Reported sales grew 6% to
$961 million, with core sales increasing 1%. Adjusted EPS rose 4% to
$1.62* (Reported EPS was
$1.92). Adjusted EBITDA increased 7% to **
$223 million**, achieving a strong 23.2% margin, up from 22.9% in the prior year.
Performance was bolstered by strong product volume growth in Pharma and Closures. Injectables sales, in particular, surged 18% in the quarter.
Q4 2025 Guidance: Aptar projects **Adjusted EPS between
$1.20 and
$1.28**. All three segments are expected to contribute positively in Q4. Management anticipates sustained Pharma pipeline growth (expected to contribute 7% to 10% of revenue annually) and continued acceleration in injectables (driven by GLP-1, Annex-1, and biologics applications), although the company expects to face tough year-over-year comparisons due to the normalization of naloxone sales.
